000177229 001__ 177229
000177229 005__ 20240229133734.0
000177229 0247_ $$2doi$$a10.1016/j.ijrobp.2021.07.1110
000177229 0247_ $$2pmid$$apmid:34701311
000177229 0247_ $$2ISSN$$a0360-3016
000177229 0247_ $$2ISSN$$a1879-355X
000177229 037__ $$aDKFZ-2021-02363
000177229 041__ $$aEnglish
000177229 082__ $$a610
000177229 1001_ $$0P:(DE-He78)80e100a16534f5fc67f7436ee67a47f9$$aRühle, Alexander$$b0$$eFirst author$$udkfz
000177229 245__ $$aDevelopment and External Validation of a Prognostic Classifier for Elderly Head-and-Neck Cancer Patients Undergoing (Chemo)radiation.
000177229 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2021
000177229 3367_ $$2DRIVER$$aarticle
000177229 3367_ $$2DataCite$$aOutput Types/Journal article
000177229 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1675085513_31442
000177229 3367_ $$2BibTeX$$aARTICLE
000177229 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000177229 3367_ $$00$$2EndNote$$aJournal Article
000177229 500__ $$a#EA:E055#LA:E055#
000177229 520__ $$aElderly head-and-neck squamous cell carcinoma (HNSCC) patients form a heterogeneous cohort, and survival estimation is often challenging due to underlying comorbidities. Prognostic classifiers and nomograms may therefore be useful for overall survival (OS) estimation in order to provide shared decision-making in the clinical routine.A total of 284 elderly HNSCC patients aged ≥65 years who received a curative (chemo)radiation between 2010 and 2020 at a tertiary cancer center were used for the development of a survival classifier. On the basis of a multivariate Cox regression analysis, significant parameters were identified for which points were given according to the beta regression values. The derived classifier was then validated in a second, external cohort consisting of 217 elderly HNSCC patients undergoing (chemo)radiation. Based on the cumulative data of 501 patients, a nomogram for the 2-year and 4-year OS was created. We then examined in a third independent cohort whether the classifier could also stratify the prognosis of surgically treated elderly HNSCC patients without adjuvant (chemo)radiation (n = 169).In the multivariate backward stepwise Cox regression with likelihood ratio tests using P < 0.1 as inclusion criterion, the Karnofsky Performance Status (KPS, HR = 2.654, P < 0.001), the age-adjusted Charlson Comorbidity Index (CCI, HR = 2.598, P < 0.001) and the pre-radiotherapy CRP serum concentration (HR = 1.634, P = 0.064) were significant prognostic parameters for OS. Following the beta regression values, a KPS ≤70% and a CCI ≥6 points were given 1 point, while a CRP concentration ≥5 mg/L was given 0.5 points. The median OS was 107 (0 points), 34 (0.5 points), 28 (1 point), 11 (1.5 points), 9 (2 points) and 6 months (2.5 points), respectively. In order to obtain considerably distinct prognostic subgroups, 3 prognostic groups were created: A favorable (0 points), an intermediate (0.5-2 points) and a poor (2.5 points) subgroup. While the median OS for the favorable group amounted to 107 months, it was 28 and 6 months for the intermediate and poor cohorts, respectively (P < 0.001, log-rank test). In the external cohort, the median OS was found to range at 130, 29 and 9 months for the favorable, intermediate and poor group, respectively (P = 0.005). Using the aggregated data of both cohorts, a nomogram based on the KPS, CCI and CRP was created for the 2-year and 4-year OS that exhibited a concordance index of 0.65 (Harrell's C). For the surgically treated cohort of elderly HNSCC patients, only the KPS ≤70% (HR = 5.950, P = 0.002) but not the CCI ≥6 points (HR = 1.937, P = 0.232) or the baseline CRP serum value (HR = 1.743, P = 0.328) were significant prognosticators.We developed and externally validated a clinically feasible survival score for elderly HNSCC patients undergoing (chemo)radiation. Both the score and nomogram may be useful aiding shared decision-making of radiation oncologists and medical oncologists treating elderly HNSCC patients.
000177229 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000177229 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000177229 7001_ $$aStromberger, C.$$b1
000177229 7001_ $$0P:(DE-HGF)0$$aHaehl, E.$$b2
000177229 7001_ $$aSenger, C.$$b3
000177229 7001_ $$aFalkenstein, A. E.$$b4
000177229 7001_ $$0P:(DE-He78)75b4c256a6de824414938cf2aaeff88e$$aStoian, R. G.$$b5$$udkfz
000177229 7001_ $$0P:(DE-HGF)0$$aZamboglou, C.$$b6
000177229 7001_ $$aKnopf, A.$$b7
000177229 7001_ $$aBudach, V.$$b8
000177229 7001_ $$0P:(DE-HGF)0$$aGrosu, A. L.$$b9
000177229 7001_ $$0P:(DE-He78)8d52e7ff1ccaac7dbf0232fdcb0168bd$$aNicolay, Nils$$b10$$eLast author$$udkfz
000177229 773__ $$0PERI:(DE-600)1500486-7$$a10.1016/j.ijrobp.2021.07.1110$$gVol. 111, no. 3S, p. e378 -$$n3S$$pe378$$tInternational journal of radiation oncology, biology, physics$$v111$$x0360-3016$$y2021
000177229 909CO $$ooai:inrepo02.dkfz.de:177229$$pVDB
000177229 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)80e100a16534f5fc67f7436ee67a47f9$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000177229 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000177229 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)75b4c256a6de824414938cf2aaeff88e$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000177229 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000177229 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000177229 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d52e7ff1ccaac7dbf0232fdcb0168bd$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000177229 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000177229 9141_ $$y2021
000177229 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2021-01-27$$wger
000177229 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-27
000177229 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-27
000177229 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-27
000177229 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-27
000177229 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-27
000177229 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-27
000177229 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-27
000177229 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-27
000177229 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-27
000177229 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J RADIAT ONCOL : 2019$$d2021-01-27
000177229 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-01-27
000177229 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-01-27
000177229 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J RADIAT ONCOL : 2019$$d2021-01-27
000177229 9201_ $$0I:(DE-He78)FR01-20160331$$kFR01$$lDKTK FR zentral$$x0
000177229 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Molekulare Radioonkologie$$x1
000177229 980__ $$ajournal
000177229 980__ $$aVDB
000177229 980__ $$aI:(DE-He78)FR01-20160331
000177229 980__ $$aI:(DE-He78)E055-20160331
000177229 980__ $$aUNRESTRICTED